We are live on ! Find out more
PBPIA

Pivotal bioVenture Partners Investment Advisor Portfolio holdings

AUM $280M
1-Year Est. Return 181.4%
This Fund
S&P 500
This Quarter Est. Return
-10.99%
1 Year Est. Return
+181.4%
3 Year Est. Return
+730.97%
5 Year Est. Return
+1,157.4%
10 Year Est. Return
–
AUM
$254M
AUM Growth
-$58M
Cap. Flow
-$9.06M
Cap. Flow %
-3.57%
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
–
Reduced
2
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$6.55M
2
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
+$2.52M
3
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$17

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$97.2M 38.31%
852,708
-56,000
-6% -$6.55M
PCVX icon
2
Vaxcyte
PCVX
$8.8B
$31.6M 12.47%
1,405,421
– –
BOLT icon
3
Bolt Biotherapeutics
BOLT
$7.71M
$29.2M 11.53%
94,573
– –
INZY
4
DELISTED
Inozyme Pharma
INZY
$27.1M 10.69%
1,591,154
– –
AKUS
5
DELISTED
Akouos Inc
AKUS
$22.5M 8.87%
1,794,088
– –
ALGS icon
6
Aligos Therapeutics
ALGS
$45.8M
$17.9M 7.04%
35,062
– –
ARQT icon
7
Arcutis Biotherapeutics
ARQT
$3.3B
$15.5M 6.12%
569,041
– –
FUSN
8
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$12.6M 4.97%
1,598,377
-2
-0% -$17
ETTX
9
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
– –
-1,176,378
Closed -$2.52M

Similar funds

HCM
Hall Capital Management Barrington, Rhode Island $280M AUM 14.82% 1-Year Est. Return
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's Q2 2021 Portfolio in Review

As of Q2 2021, Pivotal bioVenture Partners Investment Advisor held 9 positions worth $254M, down 19% from $312M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Pivotal bioVenture Partners Investment Advisor withdrew a net $9.06M in Q2 2021, closing 1 position and reducing 2 holdings. Its most notable exit was Entasis Therapeutics Holdings Inc., an estimated $2.52M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Pivotal bioVenture Partners Investment Advisor's biggest Q2 2021 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $6.55M.
  • Pivotal bioVenture Partners Investment Advisor fully exited Entasis Therapeutics Holdings Inc. in Q2 2021, selling an estimated $2.52M.
  • Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 100% of its $254M portfolio in Q2 2021.
  • Pivotal bioVenture Partners Investment Advisor opened 0 new positions and closed 1 in Q2 2021.
  • Pivotal bioVenture Partners Investment Advisor's portfolio value fell 19% quarter-over-quarter to $254M.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q2 2021, filed 16 Aug 2021.